| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/33119136_HAS_TOPIC_C0003451> <https://research.tib.eu/covid-19/entity/33119136_HAS_TOPIC_C0008976> <https://research.tib.eu/covid-19/entity/33119136_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/33119136_HAS_TOPIC_C0872152> <https://research.tib.eu/covid-19/entity/33119136_HAS_TOPIC_C1519620> <https://research.tib.eu/covid-19/entity/33119136_HAS_TOPIC_C1615608> <https://research.tib.eu/covid-19/entity/33119136_HAS_TOPIC_C3494163> <https://research.tib.eu/covid-19/entity/33119136_HAS_TOPIC_C3494164> <https://research.tib.eu/covid-19/entity/33119136_HAS_TOPIC_C5200696> <https://research.tib.eu/covid-19/entity/33119136_HAS_TOPIC_C5200697> <https://research.tib.eu/covid-19/entity/33119136_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/33119136_HAS_TOPIC_C5392141>
?:authorAffiliation	[\'dMed, Shanghai, China.\', \'Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.\', \'Sanofi (retired), Bridgewater, NJ, USA.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Cong_Danhua> <https://research.tib.eu/covid-19/entity/Geng_Donghao> <https://research.tib.eu/covid-19/entity/Knapp_Richard_J> <https://research.tib.eu/covid-19/entity/Shi_Jun> <https://research.tib.eu/covid-19/entity/Shi_Kevin_X> <https://research.tib.eu/covid-19/entity/Xiao_Yubo> <https://research.tib.eu/covid-19/entity/Zhang_Yiting>
?:doi	<https://research.tib.eu/covid-19/entity/10.1111/bcp.14629>
?:doi	10.1111/bcp.14629
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Journal_Article> <https://research.tib.eu/covid-19/entity/Review>
?:journal	British journal of clinical pharmacology
is ?:pmid of	<https://research.tib.eu/covid-19/entity/33119136>
?:pmid	<https://research.tib.eu/covid-19/entity/33119136>
?:pmid	33119136
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	1.543
?:rankingScore_hIndex	126
?:title	Challenges of drug development during the COVID-19 pandemic: Key considerations for clinical trial designs.
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>
?:year	2021

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/33119136>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/33119136>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all